NASDAQ:CPRX - Catalyst Pharmaceuticals Stock Price, Forecast & News

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) announced its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported $0.13 earnings per share for the quarter, beating analysts' consensus estimates of $0.11 by $0.02. The biopharmaceutical company earned $30.90 million during the quarter, compared to analyst estimates of $33.19 million. Catalyst Pharmaceuticals had a net margin of 12.99% and a return on equity of 15.53%. View Catalyst Pharmaceuticals' Earnings History.

Catalyst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals issued an update on its FY 2020 Pre-Market earnings guidance on Monday, January, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $135-155 million, compared to the consensus revenue estimate of $145.62 million.

4 equities research analysts have issued 1 year target prices for Catalyst Pharmaceuticals' shares. Their forecasts range from $7.00 to $12.00. On average, they expect Catalyst Pharmaceuticals' stock price to reach $9.75 in the next year. This suggests a possible upside of 115.2% from the stock's current price. View Analyst Price Targets for Catalyst Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalyst Pharmaceuticals.

News headlines about CPRX stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Catalyst Pharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the next several days. View News Stories for Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals saw a increase in short interest in January. As of January 15th, there was short interest totalling 11,830,000 shares, an increase of 32.9% from the December 31st total of 8,900,000 shares. Based on an average daily volume of 2,370,000 shares, the days-to-cover ratio is currently 5.0 days. Approximately 12.4% of the company's stock are short sold. View Catalyst Pharmaceuticals' Current Options Chain.

Some companies that are related to Catalyst Pharmaceuticals include Cambrex (CBM), Pacira Biosciences (PCRX), Epizyme (EPZM), Turning Point Therapeutics (TPTX), Xencor (XNCR), Heron Therapeutics (HRTX), Eidos Therapeutics (EIDX), Ironwood Pharmaceuticals (IRWD), Ligand Pharmaceuticals (LGND), Tricida (TCDA), Esperion Therapeutics (ESPR), BELLUS Health (BLUSF), Arvinas (ARVN), IGM Biosciences (IGMS) and Zymeworks (ZYME).

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Amarin (AMRN), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Verastem (VSTM), AcelRx Pharmaceuticals (ACRX), Exelixis (EXEL), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX) and Cognex (CGNX).

Catalyst Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (7.20%), Goldman Sachs Group Inc. (1.87%), Prudential Financial Inc. (1.72%), Marshall Wace LLP (1.52%), Geode Capital Management LLC (1.46%) and AQR Capital Management LLC (1.10%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Donald A Denkhaus, Gary Ingenito and Patrick J Mcenany. View Institutional Ownership Trends for Catalyst Pharmaceuticals.

CPRX stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Chicago Equity Partners LLC, Panagora Asset Management Inc., Cadence Capital Management LLC, Bank of America Corp DE, Geode Capital Management LLC, UBS Asset Management Americas Inc. and Jefferies Group LLC. View Insider Buying and Selling for Catalyst Pharmaceuticals.

CPRX stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Marshall Wace LLP, AQR Capital Management LLC, Goldman Sachs Group Inc., Royce & Associates LP, Prudential Financial Inc., Credit Suisse AG and Acadian Asset Management LLC. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, Donald A Denkhaus and Patrick J Mcenany. View Insider Buying and Selling for Catalyst Pharmaceuticals.

Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CPRX stock can currently be purchased for approximately $4.53.

Catalyst Pharmaceuticals has a market capitalization of $466.82 million and generates $500,000.00 in revenue each year. The biopharmaceutical company earns $-34,000,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. Catalyst Pharmaceuticals employs 51 workers across the globe.View Additional Information About Catalyst Pharmaceuticals.

The official website for Catalyst Pharmaceuticals is http://www.catalystpharma.com/.

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]